PainChek General Discussion, page-2954

I used to have RAP. It is potentially huge and it is known internationally so it generated huge interest. They even have Fidelity as a large holder.

The negatives were : The Aus results were so good like unbelievable, but then the round 1 US trails were awful and they attributed it down to lack of training and sound quality in the US hospitals. Got smashed to hell. they managed to recover and go for round 2 trials, which were okay but never as good as the Aus clinical trials, especially for Pneumonia, which was the main diagnostic disease to go for.
Now they have diversified into sleep apnoea as well, which is a way of mitigating business risk because of the issues encountered with the primary diagnostic app in the clinical phase.

What was strange is that the Australian double blind trial results from 2016 were analysed by Dr Udantha from Uni Queensland who invented the app, which seemed like a slight conflict since they were so good.

They had great results so why didnt they just commercialise in Australia if the results were valid, and even apply for CE mark using the aus results..instead they just went to the US to shoot for FDA approval with US clinical trials.

PCK have done it totally different. They proved the concept clinically with no issues, and have now commercialised into Aus and Euro, then will aim for FDA after.